[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Your Free 7-Day Premier trial ends on . Extend Your Trial For Another 30 Days. Time remaining
Faster, Cleaner, Better.

Alumis Inc (ALMS)

Alumis Inc (ALMS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,896,755
  • Shares Outstanding, K 129,435
  • Annual Sales, $ 24,050 K
  • Annual Income, $ -243,330 K
  • EBIT $ -417 M
  • EBITDA $ -414 M
  • 60-Month Beta -0.69
  • Price/Sales 124.91
  • Price/Cash Flow N/A
  • Price/Book 6.60

Options Overview Details

View History
  • Implied Volatility 202.57% (-4.63%)
  • Historical Volatility 63.60%
  • IV Percentile 80%
  • IV Rank 11.87%
  • IV High 1,143.00% on 11/12/25
  • IV Low 75.92% on 06/09/26
  • Expected Move (DTE 20) 3.91 (17.47%)
  • Put/Call Vol Ratio 0.41
  • Today's Volume 835
  • Volume Avg (30-Day) 2,638
  • Put/Call OI Ratio 0.49
  • Today's Open Interest 58,743
  • Open Int (30-Day) 36,465
  • Expected Range 18.47 to 26.29

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 11 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/26
See More
  • Average Estimate $-0.73
  • Number of Estimates 5
  • High Estimate $-0.62
  • Low Estimate $-0.80
  • Prior Year $-1.06
  • Growth Rate Est. (year over year) +31.13%

Price Performance

See More
Period Period Low Period High Performance
1-Month
22.03 +1.59%
on 08/20/26
29.20 -23.36%
on 07/31/26
-4.65 (-17.20%)
since 07/28/26
3-Month
18.36 +21.90%
on 06/09/26
31.35 -28.61%
on 07/08/26
+0.98 (+4.58%)
since 05/28/26
52-Week
3.76 +495.21%
on 09/30/25
31.35 -28.61%
on 07/08/26
+17.68 (+376.17%)
since 08/28/25

Most Recent Stories

More News
Alumis Reports Second Quarter 2026 Financial Results and Highlights Recent Achievements

– ONWARD3: 54% of patients reached complete skin clearance (PASI 100) at 48 weeks, positioning envudeucitinib to set a new standard in PsO – – Alumis remains on track to submit its New Drug...

ALMS : 22.38 (-3.58%)
Alumis Reports Second Quarter 2026 Financial Results and Highlights Recent Achievements

– ONWARD3: 54% of patients reached complete skin clearance (PASI 100) at 48 weeks, positioning envudeucitinib to set a new standard in PsO –

ALMS : 22.38 (-3.58%)
Alumis: Can Envudeucitinib's Timeline Still Justify the Post-Q1 Price Target Euphoria?

Barchart Research What to Expect from ALMS Earnings ALMS Generated August 11, 2026 Current Price $25.37 EPS Estimate $$-0.70 Consensus Rating Strong Buy Average Move 6.65% Alumis: Can Envudeucitinib's...

ALMS : 22.38 (-3.58%)
Envudeucitinib Long-term Data Positioned to Set a New Standard for Plaque Psoriasis Treatment, Delivering Highest Reported PASI 100 Skin Clearance Among Oral Therapies

– ONWARD3 data show 54% of patients reached complete skin clearance (PASI 100) after 48 weeks of continuous envudeucitinib treatment – – Favorable long - term safety and tolerability profile...

ALMS : 22.38 (-3.58%)
Alumis Reports First Quarter 2026 Financial Results and Highlights Recent Achievements

– Late - breaking oral presentation of Phase 3 envudeucitinib data in moderate - to - severe plaque psoriasis (PsO) at the 2026 American Academy of Dermatology (AAD) Annual Meeting demonstrating early...

ALMS : 22.38 (-3.58%)
Alumis Reports First Quarter 2026 Financial Results and Highlights Recent Achievements

– Late-breaking oral presentation of Phase 3 envudeucitinib data in moderate-to-severe plaque psoriasis (PsO) at the 2026 American Academy of Dermatology...

ALMS : 22.38 (-3.58%)
Alumis’ Envudeucitinib Delivers Early and Robust Improvements in Skin Clearance, Quality of Life and Psoriasis Symptoms in Two Phase 3 Trials, Underscoring Its Potential as a Leading Oral Therapy for Plaque Psoriasis

Envudeucitinib late-breaking data at AAD: early and robust improvements in skin clearance, quality of life and psoriasis symptoms in two Phase 3 trials...

ALMS : 22.38 (-3.58%)
Alumis’ Envudeucitinib Delivers Early and Robust Improvements in Skin Clearance, Quality of Life and Psoriasis Symptoms in Two Phase 3 Trials, Underscoring Its Potential as a Leading Oral Therapy for Plaque Psoriasis

Envudeucitinib achieved robust PASI responses by Week 16, with significant continued improvements by Week 24 in PASI 90 (68.0%, 62.1%) and PASI 100 (41.0%, 39.5%) Quality‑of‑life improvements...

ALMS : 22.38 (-3.58%)
Alumis Reports Year End 2025 Financial Results and Highlights Recent Achievements

– Positive Phase 3 topline results demonstrating envudeucitinib’s leading skin clearance, meaningful symptom improvement and a favorable safety profile in patients with moderate-to-severe plaque psoriasis...

ALMS : 22.38 (-3.58%)
Alumis Reports Year End 2025 Financial Results and Highlights Recent Achievements

– Positive Phase 3 topline results demonstrating envudeucitinib’s leading skin clearance, meaningful symptom improvement and a favorable safety profile in...

ALMS : 22.38 (-3.58%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Buy with a Weakening short term outlook on maintaining the current direction.

See More Share

Business Summary

Alumis Inc. is a clinical-stage biopharmaceutical company developing oral therapies using a precision approach to optimize clinical outcomes and significantly improve the lives of patients with immune-mediated diseases. The company's product candidate includes ESK-001. Alumis Inc. is based in SOUTH SAN...

See More

Key Turning Points

3rd Resistance Point 23.92
2nd Resistance Point 23.60
1st Resistance Point 22.99
Last Price 22.38
1st Support Level 22.06
2nd Support Level 21.74
3rd Support Level 21.13

See More

52-Week High 31.35
Last Price 22.38
Fibonacci 61.8% 20.81
Fibonacci 50% 17.56
Fibonacci 38.2% 14.30
52-Week Low 3.76

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.